ASND — Ascendis Pharma A/S Income Statement
0.000.00%
Last trade - 00:00- $9.96bn
- $10.30bn
- €363.64m
Annual income statement for Ascendis Pharma A/S, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.95 | 7.78 | 51.2 | 267 | 364 |
| Cost of Revenue | |||||
| Gross Profit | — | 4.25 | 39 | 222 | 319 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 338 | 460 | 613 | 722 | 642 |
| Operating Profit | -331 | -452 | -562 | -456 | -279 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -419 | -384 | -578 | -474 | -373 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -419 | -384 | -583 | -481 | -378 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -419 | -384 | -583 | -481 | -378 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -419 | -384 | -583 | -481 | -378 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.28 | -7 | -10.4 | -8.46 | -6.53 |